News
| 28 November 2019 |
Holding(s) in Company TR-1: Standard form for notification of major holdingsLONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings |
| 27 November 2019 |
Verona Pharma plc: Grant of Options to PDMRLONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.… |
| 18 November 2019 |
Verona Pharma plc: PDMR Dealing – Purchase by ChairmanLONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company… |
| 14 November 2019 |
Verona Pharma plc: PDMR Dealing – Purchase by ChairmanLONDON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company th… |
| 13 November 2019 |
Verona Pharma to Present at Jefferies 2019 London Healthcare ConferenceLONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, will present a corporate… |
| 11 November 2019 |
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New YorkLONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, and Piers Morgan, CFO, will… |
| 5 November 2019 |
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019Reported positive Phase 2 data with dry powder inhaler formulation |
| 29 October 2019 |
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development UpdateLONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that it will report its financial results for the three and nine mo… |
| 17 October 2019 |
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDLONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the… |
| 15 October 2019 |
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifent… |
Targeting unmet needs
384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients
Read more about COPD and CF in the unmet needs section of this website
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2019
